Clinical Trials Logo

Immune Checkpoint Inhibitor clinical trials

View clinical trials related to Immune Checkpoint Inhibitor.

Filter by:

NCT ID: NCT04470440 Completed - Prognosis Clinical Trials

Thyroid Dysfunction and Nivolumab Reponse in NSCLC

THYRONIVO
Start date: October 22, 2019
Phase:
Study type: Observational

This is an observational, retrospective and monocentric study, conducted at the university Hospital of Brest The primary objective is to assess the association between the occurrence of thyroid dysfunction in patients treated with Nivolumab® for a non-small cell lung cancer and prognosis and therapeutic response The second objective is to assess prognosis and therapeutic response according to severity and subtype of thyroid dysfunction

NCT ID: NCT04419441 Recruiting - Hodgkin Lymphoma Clinical Trials

Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

ICI-RT-1
Start date: June 24, 2020
Phase:
Study type: Observational

This is an observational retrospective study to investigate the efficacy and safety of the treatment with an immune checkpoint inhibitor (nivolumab or pembrolizumab) in combination with radiotherapy in patients with relapsed/refractory classical Hodgkin lymphoma.

NCT ID: NCT04414969 Recruiting - Chemotherapy Effect Clinical Trials

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Start date: June 26, 2020
Phase: Phase 2
Study type: Interventional

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.